Acadian Asset Management LLC Boosts Stake in Fluidigm Co. (FLDM)

Acadian Asset Management LLC grew its holdings in Fluidigm Co. (NASDAQ:FLDM) by 11.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 476,063 shares of the medical research company’s stock after acquiring an additional 49,972 shares during the quarter. Acadian Asset Management LLC’s holdings in Fluidigm were worth $3,566,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of FLDM. LMR Partners LLP bought a new stake in shares of Fluidigm in the second quarter valued at approximately $144,000. Wells Fargo & Company MN boosted its position in shares of Fluidigm by 64.8% in the first quarter. Wells Fargo & Company MN now owns 28,945 shares of the medical research company’s stock valued at $169,000 after acquiring an additional 11,377 shares during the period. Fairpointe Capital LLC bought a new stake in shares of Fluidigm in the second quarter valued at approximately $238,000. Los Angeles Capital Management & Equity Research Inc. bought a new stake in shares of Fluidigm in the second quarter valued at approximately $240,000. Finally, Paloma Partners Management Co boosted its position in shares of Fluidigm by 234.7% in the second quarter. Paloma Partners Management Co now owns 56,900 shares of the medical research company’s stock valued at $339,000 after acquiring an additional 39,900 shares during the period. 96.55% of the stock is owned by institutional investors.

Shares of NASDAQ FLDM opened at $7.90 on Friday. The company has a debt-to-equity ratio of 4.79, a current ratio of 2.05 and a quick ratio of 1.64. The firm has a market capitalization of $286.68 million, a P/E ratio of -6.64 and a beta of 2.84. Fluidigm Co. has a one year low of $4.45 and a one year high of $8.62.

Fluidigm (NASDAQ:FLDM) last issued its earnings results on Thursday, November 1st. The medical research company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.20). The firm had revenue of $28.96 million during the quarter, compared to analyst estimates of $27.50 million. Fluidigm had a negative net margin of 50.46% and a negative return on equity of 77.14%. Equities analysts anticipate that Fluidigm Co. will post -0.99 EPS for the current year.

Several equities research analysts have recently weighed in on the company. BidaskClub raised Fluidigm from a “hold” rating to a “buy” rating in a research report on Wednesday, September 12th. Zacks Investment Research upgraded Fluidigm from a “sell” rating to a “hold” rating in a research note on Thursday, September 20th. Finally, Piper Jaffray Companies upgraded Fluidigm from a “neutral” rating to an “overweight” rating in a research note on Friday, November 2nd.

In other news, insider Levin Capital Strategies, L.P. bought 25,500 shares of the business’s stock in a transaction that occurred on Wednesday, August 15th. The stock was acquired at an average cost of $6.78 per share, for a total transaction of $172,890.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders purchased 99,785 shares of company stock valued at $721,409 over the last 90 days. 2.20% of the stock is currently owned by corporate insiders.

WARNING: “Acadian Asset Management LLC Boosts Stake in Fluidigm Co. (FLDM)” was first posted by WKRB News and is owned by of WKRB News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.wkrb13.com/2018/11/09/acadian-asset-management-llc-boosts-stake-in-fluidigm-co-fldm.html.

Fluidigm Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Featured Article: Why investors pay attention to retained earnings

Want to see what other hedge funds are holding FLDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fluidigm Co. (NASDAQ:FLDM).

Institutional Ownership by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply